Participants' assessment of global function (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) showed no clear difference in participants' assessment of global function (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Number of tender sites on muscles of mastication (palpation index) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) led to lower number of tender sites on muscles of mastication (palpation index) compared with placebo; GRADE not reported.
1 finding from 1 review
Spontaneous pain in the TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) led to lower spontaneous pain in the TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
Comparison 2: anticonvulsants/GABAs probably leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 2: anticonvulsants/GABAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Abstinence · cannabis dependence
It is very uncertain whether anticonvulsants and mood stabilisers changes participants abstinent at end of treatment compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
It is very uncertain whether anticonvulsants and mood stabilisers changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Completion of scheduled treatment · cannabis dependence
Anticonvulsants and mood stabilisers may leads to lower completion of scheduled treatment compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: drowsiness (gabapentin alone) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day) changes adverse effects: drowsiness (gabapentin alone) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 3: anticonvulsant levetiracetam changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
Comparison 3: anticonvulsant levetiracetam showed no clear difference in global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin + alpha lipoic acid) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: mild headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin + alpha lipoic acid) changes adverse effects: mild headache compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review